Optimizing Flow Cytometry Quantitation of Rare-Cell Populations and Its Application In Immunotherapy
Eurofins Viracor invites you to add the upcoming event to your calendar. This informative webinar, featuring our flow cytometry expert, Dr. Brian Maybruck, will focus on the use of Flow Cytometry for rare cell quantitation, and its application in drug development.
Multiparameter flow cytometry applications and future outlook
Flow cytometry is a very powerful and reliable alternative to many other methods used for clinical drug development. Consider that it can simultaneously measure multiple parameters on tens of thousands of cells, with a resolution down to a single cell level, robustly and rapidly (greater than 1000 samples per day).
Immunogenicity Assay Development, Validation & Transfer in a Vaccine Candidate Clinical Trial
A large global pharmaceutical company, with a promising new vaccine candidate, partnered with Viracor Eurofins to perform immunogenicity testing as part of their clinical trial development. Several specific areas of expertise were called upon to enable the Viracor team to deliver multiple precise, robust and sensitive assays to meet the sponsor's needs.
Clinical Development Testing Services Info Sheet for Cell & Gene Therapy
Immunotherapies have emerged as some of the most promising approaches to treating cancer patients. Download the Info Sheet to see what assay development and testing services Viracor Eurofins offers for supporting clinical development of Cell & Gene therapy candidates.
Validation and Transfer of Biodistribution and Viral Shedding Assays In Development of An Oncolytic Virus Immunotherapy Candidate
Several new immunotherapy technologies, such as cancer vaccines, adoptive cell (CAR T-cell), and checkpoint inhibitor therapies, have emerged as promising approaches to treating cancer patients. Oncolytic virus therapies in particular, combine selective tumor cell killing and induction of anti-cancer immune reactions. Among the most significant safety and efficacy concerns in development of this new class of drugs are neutralization and clearance of virus particles. Check out this case study to learn about methods used to help characterize the biodistribution and transmissibility of an oncolytic virus candidate in a clinical trial.